Tirzepatide monograph · Evidence review
Tirzepatide vs Semaglutide: Head-to-Head
How tirzepatide and semaglutide compare in the trials that put them head-to-head — SURPASS-2 for glucose, SURMOUNT-5 for weight loss. The honest verdict.
Researched & written by Alan Pierce · last updated
Clinical Pharmacology Writer
Tirzepatide and semaglutide are the two most talked-about incretin medicines, and the most useful question is not which one is "best" in the abstract but how they perform when they are tested against each other in the same trial. Two randomized head-to-head studies answer that directly: SURPASS-2 for blood-glucose control in type 2 diabetes, and SURMOUNT-5 for weight loss in obesity. Both favored tirzepatide, but the details and the caveats matter.
The key mechanistic difference
Semaglutide activates a single incretin receptor, the GLP-1 receptor. Tirzepatide is a dual agonist: one molecule that activates both the GIP receptor and the GLP-1 receptor1. (Tirzepatide is sold under two brand names for two indications — see Mounjaro vs Zepbound — but it is the same molecule either way.) These pathways act together on the pancreas, the brain's appetite centers, and other cardiometabolic tissues1. The added GIP activity is the leading explanation for tirzepatide's larger effects in head-to-head testing — though "different mechanism" does not automatically mean "better for every person," and tolerability still depends on the dose you reach.
§ Table 1 — Drug Comparison
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| FDA approvals | Type 2 diabetes (Mounjaro); obesity/overweight (Zepbound) | Type 2 diabetes (Ozempic); obesity/overweight (Wegovy) |
| Receptor targets | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Dosing schedule | Once weekly SC injection; 2.5–15 mg dose range | Once weekly SC injection; 0.25–2.4 mg dose range |
| HbA1c reduction (SURPASS-2 / SUSTAIN) | −2.01 to −2.30% (5–15 mg vs sema 1 mg) | −1.86% (1 mg; SURPASS-2 comparator) |
| Body-weight reduction (obesity trials) | −20.9% at 15 mg (SURMOUNT-1) | −15.2% at 2.4 mg (STEP 1) |
| Head-to-head weight loss (SURMOUNT-5) | Greater reduction vs sema 2.4 mg (p<0.001) | Reference arm (2.4 mg maximum-tolerated) |
| GI side-effect profile | Nausea, diarrhea, vomiting — dose-dependent | Nausea, diarrhea, vomiting — dose-dependent |
Glycemic control: SURPASS-2
SURPASS-2 was an active-comparator phase 3 trial in adults with type 2 diabetes that pitted tirzepatide (5, 10, and 15 mg) directly against semaglutide 1 mg once weekly. Tirzepatide produced greater reductions in HbA1c and greater weight loss than semaglutide 1 mg, while the two drugs had a broadly similar gastrointestinal side-effect profile2. This is the cleanest glycemic comparison available, and it is the basis for the common claim that tirzepatide edges out semaglutide on glucose control.
One important caveat: the comparator was semaglutide 1 mg, which is the standard diabetes (Ozempic) dose, not the higher 2.4 mg dose used for obesity. So SURPASS-2 answers the diabetes question, not the obesity question.
Weight loss: SURMOUNT-5
For obesity, the definitive head-to-head is SURMOUNT-5. It compared maximum-tolerated tirzepatide against maximum-tolerated semaglutide 2.4 mg in adults with obesity who did not have diabetes — a fairer obesity matchup because both drugs were pushed to their highest tolerated obesity doses. Tirzepatide produced significantly greater weight loss than semaglutide3. This result is consistent with the broader trial record: in its own pivotal obesity study, SURMOUNT-1, tirzepatide reached roughly 21% mean weight reduction at 15 mg4.
It is worth keeping perspective here. Semaglutide 2.4 mg is itself a highly effective weight-loss drug; SURMOUNT-5 shows tirzepatide was better on average, not that semaglutide failed. Individual responses vary, and the right choice often comes down to tolerability, cost, insurance coverage, and availability rather than the trial average alone. A larger average effect in a trial also says nothing about which drug a specific person will tolerate best or respond to most; some people do better on semaglutide despite the group averages.
§ Evidence Summary — Head-to-Head Data
| Outcome / Endpoint | Evidence strength | Grade |
|---|---|---|
| Glycemic superiority (T2D) — SURPASS-2 Phase 3 RCT, n=1879; tirzepatide 5–15 mg vs semaglutide 1 mg; all doses superior on HbA1c (PMID 34170647). | Strong | |
| Weight-loss superiority (obesity) — SURMOUNT-5 Phase 3b RCT, n=751; maximum-tolerated doses; tirzepatide significantly greater weight loss (PMID 40353578). | Strong | |
| Comparable GI tolerability — SURPASS-2 Similar proportions of GI adverse events observed; no formal non-inferiority test was pre-specified. | Moderate | |
| Cardiovascular outcomes superiority No completed head-to-head CVOT; SURPASS-CVOT (tirzepatide) and SELECT (semaglutide) were separate trials with different populations. | None |
What the head-to-head data does not settle
Two head-to-head trials are a strong foundation, but they have boundaries worth naming. SURPASS-2 and SURMOUNT-5 measured glucose and weight; they were not designed as long-term cardiovascular-outcomes trials, so claims about which drug better prevents heart attacks or strokes go beyond what these specific comparisons show. The trials also enrolled defined populations under careful titration and counseling, so the head-to-head margins seen on average may narrow or widen in everyday practice. And because the comparator dose differed between the two studies — semaglutide 1 mg in SURPASS-2 versus 2.4 mg in SURMOUNT-5 — it is important not to mix the diabetes and obesity results together. The fair reading is narrow and honest: at the doses tested, for the outcomes measured, tirzepatide came out ahead.
Side effects: similar class, manageable during titration
Both drugs share the same dominant side-effect category: gastrointestinal events such as nausea, diarrhea, vomiting, and constipation. Across the tirzepatide trial program these are generally mild to moderate, dose-dependent, most frequent during dose escalation, and the leading reason people discontinue5. SURPASS-2 found a broadly similar GI profile between the two drugs2. The practical implication is the same for both: titrate slowly and expect some queasiness early on. The detailed schedule is in the tirzepatide dosing ladder and side effects guide.
The honest verdict
Where they have been tested head-to-head, tirzepatide came out ahead: greater HbA1c and weight reductions versus semaglutide 1 mg in SURPASS-22, and greater weight loss versus semaglutide 2.4 mg in SURMOUNT-53. But both are FDA-approved, prescription-only medicines that require ongoing use, both are titrated up a dose ladder, and both share the same GI tolerability tradeoff. "Better on average in a trial" is not the same as "better for you" — that decision belongs with a qualified prescriber. For the full evidence base on tirzepatide, see the tirzepatide evidence guide, and to weigh your options start with our best tirzepatide overview. And if you are wondering what comes after both drugs, see how the investigational triple agonist stacks up in retatrutide vs tirzepatide. And for how tirzepatide compares with the older daily GLP-1 drug, see Saxenda vs Zepbound — or, if you want a needle-free option, why there is still no oral tirzepatide pill (and what the oral GLP-1 in the pipeline actually is). The two drugs are also racing on a new front — liver disease — where semaglutide currently has the phase 3 data; see tirzepatide for fatty liver (MASH).
Frequently asked questions
Is tirzepatide more effective than semaglutide?
In head-to-head trials, yes on average: tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg in SURPASS-2, and greater weight loss than semaglutide 2.4 mg in SURMOUNT-5. Individual results vary, and the better choice depends on tolerability, cost, and coverage.
What is the main difference between the two drugs?
Semaglutide activates only the GLP-1 receptor, while tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. The added GIP activity is the leading explanation for tirzepatide's larger effects in head-to-head trials.
Do they have different side effects?
Both share the same dominant side effects — gastrointestinal events such as nausea, diarrhea, vomiting, and constipation. SURPASS-2 found a broadly similar GI profile between the two. Both are managed by titrating the dose up slowly.
Which dose of semaglutide was used in the comparisons?
SURPASS-2 compared tirzepatide against semaglutide 1 mg (the standard diabetes dose). SURMOUNT-5 used maximum-tolerated semaglutide 2.4 mg (the obesity dose), making it the fairer head-to-head for weight loss.
References(5)
- Hammoud R, Drucker DJ (2023). Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.. Nature Reviews Endocrinology. PMID: 36509857. https://pubmed.ncbi.nlm.nih.gov/36509857/
- Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. New England Journal of Medicine. PMID: 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, and SURMOUNT-5 Trial Investigators (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Lin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, Li Y (2023). Weight loss efficiency and safety of tirzepatide: A Systematic review.. PLoS One. PMID: 37141329. https://pubmed.ncbi.nlm.nih.gov/37141329/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related monograph sections
Tirzepatide: Evidence, Dosing & Side Effects
An evidence-based guide to tirzepatide: how the dual GIP/GLP-1 drug works, what the trials show, the dosing ladder, side effects, and the ongoing-use reality.
ReadTirzepatide Dosing Ladder & Side Effects
The tirzepatide titration schedule from the FDA label, why the dose climbs slowly, the common GI side effects, and practical ways to manage tolerability.
ReadWhat Happens If You Stop Tirzepatide?
What the SURMOUNT-4 trial shows about weight regain after stopping tirzepatide, and why it is an ongoing therapy rather than a short course.
ReadZepbound Side Effects: Full Breakdown by Frequency
Every Zepbound (tirzepatide) side effect from the FDA label, ranked by frequency — plus the gallbladder, pancreatitis, and thyroid warnings explained.
ReadZepbound for Sleep Apnea: The New FDA Indication
In Dec 2024 the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity. What SURMOUNT-OSA showed, and why it's an adjunct, not a CPAP cure.
ReadHow & Where to Inject Zepbound: Step-by-Step (Pen & Vial)
A label-sourced walkthrough of injecting Zepbound (tirzepatide) — the pen, the vial, where to inject, site rotation, timing, storage, and sharps disposal.
ReadRetatrutide vs Tirzepatide: The Next-Gen Triple Agonist
Retatrutide's Phase 2 weight-loss numbers beat tirzepatide's — but it is still investigational and not FDA-approved. An honest, evidence-based comparison.
ReadHow Long Do Zepbound Side Effects Last?
Most Zepbound side effects are tied to dose increases and ease within days to a couple of weeks. Here is the honest timeline — and what doesn't follow it.
ReadDoes Zepbound Cause Hair Loss?
Zepbound's label lists hair loss in about 4-5% of users. The honest answer: it is almost certainly weight-loss shedding, not the drug attacking follicles.
ReadZepbound and Alcohol: What to Know
Zepbound has no labeled alcohol warning, but the honest answer is nuanced: overlapping GI effects, hypoglycemia and pancreatitis risk, and a craving signal.
ReadTirzepatide Dosage Chart: Full Titration Schedule
The complete tirzepatide titration chart from the FDA Zepbound and Mounjaro labels — every dose, every step, week by week, with the rules behind each.
ReadHow Many Units Is 2.5 mg of Tirzepatide?
There is no single unit answer for 2.5 mg of tirzepatide — it depends entirely on the compounded vial's concentration. Here's the math, and why it's risky.
ReadWhat Dose of Zepbound Is Most Effective?
Zepbound weight loss climbs with dose — 15 mg lost the most in SURMOUNT-1. But the most effective dose isn't always the highest one you can take.
ReadZepbound Cost, Coupons & the Cheapest Ways to Get It (2026)
List price, LillyDirect self-pay vials, the savings card, GoodRx-style coupons and compounded options — an honest, dated breakdown of what Zepbound costs.
ReadDoes Insurance Cover Zepbound? (Aetna, Medicare, BCBS & More) — 2026
Whether Aetna, BCBS, Cigna or Medicare cover Zepbound, why obesity-drug exclusions and prior auth block it, and how to appeal — an honest, dated guide.
ReadZepbound Results: How Much Weight Can You Lose (and How Fast)?
Trial-grounded Zepbound results: average weight loss by dose and week from SURMOUNT-1, why it takes months not weeks, and how regain works.
ReadZepbound Maintenance Dose After Goal Weight: What the Evidence Says
There's no single Zepbound maintenance dose. SURMOUNT-4 shows weight returns when you stop, so most people stay on an effective dose long term.
ReadZepbound Reviews: What Real Users (and the Trials) Report
An honest synthesis of what Zepbound reviews commonly say — efficacy, GI side effects, injection ease — set against the SURMOUNT trial data and FDA label.
ReadOral Tirzepatide: Is There a Pill? (Tablets & the Pipeline)
There is no FDA-approved oral tirzepatide — it is injectable-only. The oral GLP-1 pill in the pipeline is orforglipron, a different drug. An honest guide.
ReadSaxenda vs Zepbound: How They Compare
Saxenda (daily liraglutide) vs Zepbound (weekly tirzepatide): mechanism, average weight loss across trials, dosing, side effects, and cost, honestly compared.
ReadTirzepatide Constipation: Why It Happens and How to Get Relief
Constipation hits 11–17% of tirzepatide users in the FDA label. Here is why it happens, what eases it, and the red flags that mean call a clinician.
ReadDoes Tirzepatide Make You Tired? The Honest Answer
Fatigue is a modest tirzepatide side effect (about 5–7% vs 3% placebo). Here is why it usually happens — and the practical, mostly-secondary fixes.
ReadTirzepatide Sulfur Burps: Why They Happen and How to Stop Them
Rotten-egg sulfur burps are a common but anecdotal tirzepatide complaint, not a trial side effect. Here is the likely mechanism and what actually helps.
ReadTirzepatide and Acid Reflux/Heartburn: Why It Happens and What Helps
Tirzepatide can worsen acid reflux and heartburn in a dose-linked minority. Here is the mechanism, what the evidence shows, and the steps that actually ease it.
ReadDoes Tirzepatide Cause Muscle Loss?
In SURMOUNT-1, ~25% of weight lost on tirzepatide was lean mass — the same as placebo. What that means, and how protein and resistance training protect muscle.
ReadWhat to Eat on Tirzepatide (and Foods to Avoid)
An evidence-grounded food guide for tirzepatide: prioritize protein, fiber, and fluids; limit greasy, fried, sugary, and carbonated foods that worsen nausea.
ReadHow Much Protein on Tirzepatide for Muscle
To protect muscle on tirzepatide, aim for ~1.2–1.6 g of protein per kg daily (≈75–130 g), spread across meals, paired with resistance training.
ReadTirzepatide Weight-Loss Plateau: Why It Happens and What to Do
A tirzepatide plateau — under ~1% change over 4–6 weeks — is usually normal metabolic adaptation, not failure. Why it happens and the evidence-based responses.
ReadZepbound, Birth Control, and Pregnancy: What the Label Says
Zepbound's FDA label warns oral birth control can be less effective — use a non-oral method or backup for 4 weeks after starting and after each dose increase.
ReadStopping Tirzepatide Before Surgery and Anesthesia
Why tirzepatide is often paused before surgery for aspiration risk, what the FDA label and anesthesia guidance say, and how long to hold it.
ReadTirzepatide and Gallbladder Problems
How often tirzepatide causes gallstones and cholecystitis, why rapid weight loss is part of it, and the red-flag symptoms that need urgent care.
ReadTirzepatide Thyroid Cancer Warning Explained
What tirzepatide's boxed thyroid C-cell tumor warning actually means: verbatim FDA label text, the rat data behind it, and what human evidence shows.
ReadMounjaro vs Zepbound: Same Drug, Different Approvals
Mounjaro and Zepbound are the identical tirzepatide molecule. What differs is the FDA indication, insurance coverage, and packaging — not the potency.
ReadSwitching From Semaglutide to Tirzepatide
There is no 1:1 dose conversion. You restart tirzepatide at 2.5 mg regardless of your prior semaglutide dose — and the GI side effects re-titrate. Here's why.
ReadTirzepatide Storage: How Long Out of the Fridge?
Per the FDA label, an unopened tirzepatide pen or vial can sit at room temperature (≤86°F) for up to 21 days. Never refreeze it. The exact rules, quoted.
ReadTirzepatide and Vision Loss (NAION): What the Evidence Actually Shows
A rare optic-nerve stroke (NAION) is linked to GLP-1 drugs. The signal is strongest for semaglutide; tirzepatide-specific evidence is thin and not on the label.
ReadTirzepatide Injection-Site Reactions: Lumps, Itching, and Redness
Lumps, itching, and redness where you inject tirzepatide are usually mild and self-limiting. Why they happen, how to ease them, and the escalation signs.
ReadTirzepatide Diarrhea: Why It Happens and When to Worry
Diarrhea hits about 19–23% of tirzepatide users on the FDA label. Why it happens, when it settles, and the dehydration red flags that mean call a clinician.
ReadTirzepatide and Your Kidneys: AKI Risk, Explained Honestly
Tirzepatide isn't toxic to the kidneys — and may protect them. The real risk is indirect acute kidney injury from dehydration. What the label and trials show.
ReadTirzepatide and Pancreatitis: How Real Is the Risk?
Pancreatitis on tirzepatide is rare (~0.2–0.4% in trials, not above comparators) but FDA-label-warned. The radiating back-pain red flag and what to do.
ReadTirzepatide for PCOS, Fertility & 'Ozempic Babies'
Tirzepatide isn't FDA-approved for PCOS, but weight loss can restore ovulation — raising real unplanned-pregnancy risk. Why it's contraindicated in pregnancy.
ReadTirzepatide and Pregnancy: What the Label and the Evidence Say
Tirzepatide (Zepbound, Mounjaro) is not for use in pregnancy: the FDA label says stop it when pregnancy is recognized. Here is the guidance and the human data.
ReadIs Compounded Tirzepatide Still Legal in 2026?
Tirzepatide's shortage ended in 2024 and FDA's compounding grace period closed in early 2025. Here's the precise legal status of compounded tirzepatide in 2026.
ReadFoods to Avoid on Tirzepatide (and Why They Trigger Symptoms)
High-fat, fried, sugary, carbonated, and alcoholic foods compound tirzepatide's delayed gastric emptying — here's what to limit and the mechanism behind each.
ReadBest Time & Day to Inject Tirzepatide: What the Label Says
The FDA label allows tirzepatide at any time of day, with or without food. Why timing barely affects results — and the one switching-day rule that matters.
ReadMissed a Tirzepatide Dose? The FDA 4-Day Rule, Explained
Missed your weekly Zepbound or Mounjaro shot? The FDA label rule: take it within 4 days (96 hours), skip it if more time has passed, and never double up.
ReadOrforglipron (Foundayo): The First Oral Non-Peptide GLP-1, Explained
Orforglipron is a once-daily oral GLP-1 pill, FDA-approved as Foundayo. The ATTAIN/ACHIEVE trial data, side effects, and how it compares to tirzepatide.
ReadTirzepatide for Fatty Liver (MASH): What the Approval Means
Tirzepatide cleared MASH in ~62% of patients at 15 mg in a phase 2 trial — but it is NOT FDA-approved for fatty liver, and long-term outcomes are unproven.
ReadTirzepatide and Heart Failure (HFpEF): The SUMMIT Data
The SUMMIT trial cut worsening-heart-failure events and improved quality of life in HFpEF with obesity — but tirzepatide is NOT FDA-approved for heart failure.
ReadZepbound vs Foundayo (Orforglipron): Pill vs Shot
Zepbound is the injectable dual GIP/GLP-1; Foundayo (orforglipron) is the new oral GLP-1 pill. An honest head-to-head on efficacy, convenience, and price.
ReadIs Zepbound Worth It? An Evidence + Cost Reality Check
A balanced decision framework: ~15-21% average weight loss weighed against ~$449-574/mo cash cost, the early GI side effects, and regain after stopping.
ReadTirzepatide and Chronic Kidney Disease (CKD)
Post-hoc trial data suggest tirzepatide may protect the kidneys and cut albuminuria — but there's no FDA kidney indication. Signal vs approval, honestly.
ReadBest Telehealth Providers for Zepbound Online (2026)
An honest roundup of where to get brand Zepbound online — LillyDirect, Ro, LifeMD, Found, Sesame — and which cheap 'GLP-1' offers aren't real Zepbound.
ReadZepbound Vials vs Pens: The Self-Pay Price Difference
Zepbound comes as single-dose vials and auto-injector pens. The vials are cheaper self-pay — but vial-only, ~45-day refill, syringe-draw. An honest comparison.
ReadTirzepatide vs Orforglipron: Are These Two "Oral" Options the Same?
"Oral tirzepatide" and orforglipron are NOT the same drug. One is an unproven compounded troche; the other is FDA-approved Foundayo. The disambiguation.
ReadMochi Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)
An honest 2026 review of Mochi Health's tirzepatide — cost, the compounded-vs-brand question, how the telehealth model works, and the catches.
ReadRo Tirzepatide Review: Cost, How It Works & Honest Verdict (2026)
An honest 2026 review of Ro's tirzepatide (Zepbound) program — how much it costs, how the telehealth model works, brand vs compounded, and the catches.
ReadHenry Meds Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)
An honest 2026 review of Henry Meds' tirzepatide — cost, the compounded-vs-brand question, how the flat-fee telehealth model works, and the catches.
ReadDoes Medicare Cover Tirzepatide (Mounjaro/Zepbound)? — 2026 Guide
Medicare's statutory weight-loss exclusion, why the OSA and diabetes indications can change the answer, the savings-card lockout, and the 2026 TrumpRx deal.
ReadTirzepatide and Metformin Together: Can You Take Both?
Can you take metformin and tirzepatide together? They work by different mechanisms, are commonly co-prescribed, and the SURPASS trials were run on metformin.
ReadMetformin vs Tirzepatide: How They Compare for Weight and Blood Sugar
Metformin vs tirzepatide for weight loss and blood sugar — the honest efficacy gap, cost and side-effect tradeoffs, and why they're often combined.
ReadTirzepatide and Antidepressants: What to Know About Taking Both
Can you take tirzepatide with antidepressants? No known major drug interaction, but GI overlap and weight effects matter — review specifics with a prescriber.
ReadTirzepatide for Prediabetes: What the Evidence Shows
Tirzepatide for prediabetes — the honest evidence on reverting to normal glucose, the weight-driven benefit, and why it's off-label.
ReadTirzepatide and Coffee/Caffeine: Is It Safe?
Can you drink coffee on Mounjaro or Zepbound? No direct drug interaction, but tirzepatide's slowed stomach changes how caffeine feels. The honest picture.
ReadExercise on Tirzepatide: Why It Matters More Than You Think
Exercise on tirzepatide matters more than most expect: resistance training plus protein protects muscle and your metabolic rate during the weight-loss deficit.
ReadTirzepatide and Sleep: Better Rest or Disrupted Nights?
Tirzepatide's effect on sleep is mixed: it's FDA-approved for sleep apnea and weight loss improves rest, but early side effects can disrupt nights.
ReadTirzepatide and Libido: Does It Raise or Lower Sex Drive?
There's no direct tirzepatide-libido trial. Effects are mostly indirect: weight loss often helps sex drive, but a deficit or fatigue can blunt it.
ReadTirzepatide Microdosing: What It Means and What the Evidence Says
"Microdosing" tirzepatide means using doses below the approved schedule. Here is what the label and the SURMOUNT-1 dose-response data actually show.
ReadTirzepatide and Nausea: Why It Happens and How to Manage It
Nausea is tirzepatide's most common side effect — roughly a quarter to a third of users. Why it happens, when it peaks, and practical ways to reduce it.
ReadDoes Zepbound Lower Blood Pressure?
In SURMOUNT-1's blood-pressure substudy, tirzepatide cut 24-hour systolic BP by 7-11 mm Hg. But Zepbound is not a hypertension drug. The honest evidence.
Read